Download PDF
Thromb Haemost 1961; 05(02): 285-295
DOI: 10.1055/s-0038-1654925
Originalarbeiten – Original Article – Travaux Originaux
Schattauer GmbH

Studies on Paracoagulation. Role of Antithrombin VI

Maria Kopeć
1   Laboratory of Clinical Biochemistry Institute of Hematology, Warsaw
,
Edward Kowalski
1   Laboratory of Clinical Biochemistry Institute of Hematology, Warsaw
,
Jolanta Stachurska
1   Laboratory of Clinical Biochemistry Institute of Hematology, Warsaw
› Author Affiliations
Further Information

Publication History

Publication Date:
21 June 2018 (online)

    Permissions and Reprints

Summary

1. Conditions in which paracoagulation occurs were studied.

2. It could be shown, that instead of protamine sulphate and toluidine blue, lysozyme, cooling to 4° C and acidification to pH 5,3—6,1 induce paracoagulation.

3. Paracoagulation could be obtained in the presence of antithrombin VI in purified systems consisting either of fibrinogen or fibrin monomer.

4. It could be stated, that antithrombin VI inhibits the polymerization of fibrin monomer and probably interferes with the protease activity of thrombin.

5. Paracoagulating factors overcome the inhibitory action of antithrombin VI.

6. The significance of the above findings is discussed.

 

  • References

  • 1 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv för Kemi. 10: 415 1956;
    PubMedGoogle Scholar
  • 2 Bomchil G, Derechin M. Fibrinolyse hémorragique mortelle par gastrectomie. Prévues diagnostiques basées sur la paracoagulation fibrinolytique. Revue Hématol. 10: 41 1955;
    PubMedGoogle Scholar
  • 3 Derechin M. Caractères généraux de la paracoagulation fibrinolytique. Revue Hématol. 10: 35 1955;
    PubMedGoogle Scholar
  • 4 Derechin M, Szuchet S. Fibrinolytic paracoagulation with different substances. Acta physiol, latinoamericana 06: 170 1956;
    PubMedGoogle Scholar
  • 5 Donnely T. H, Laskowski Jr M, Nolley N, Scheraga H. A. Equilibria in the fibrinogen-fibrin conversion. II. Reversibility of the polymerisation steps. Arch. Biochem 56: 369 1955;
    PubMedGoogle Scholar
  • 6 Kekwick R. A, Mackay M. E, Nance M. H, Record B. R. The purification of human fibrinogen. Bioch. J. 60: 671 1955;
    PubMedGoogle Scholar
  • 7 Kline D. L. The purification and cristalisation of plasminogen pro. fibrinolysin J biol Chem. 204: 949 1953;
    PubMedGoogle Scholar
  • 8 Lewis J. H, Ferguson J. H. Partial purification of human prothrombin and proconvertin; their characteristics and interaction. J. clin. Invest 32: 915 1953;
    CrossrefPubMedGoogle Scholar
  • 9 Niewiarowski S, Kowalski E. Un nouvel anticoagulant dérivé du fibrinogène. Révue Hématol. 13: 320 1958;
    PubMedGoogle Scholar
  • 10 Niewiarowski S, Kowalski E, Stachurska J. Influence of fibrinogen derived antithrombin (antithrombin VI) on the blood coagulation system. Acta bioch. polon. 06: 43 1959;
    PubMedGoogle Scholar
  • 11 Scheraga H. A, Laskowski Jr M. The fibrinogen-fibrin conversion. Advances in Protein Chem. 12: 1 1957;
    PubMedGoogle Scholar
  • 12 Triantaphylopouios D. C. Nature of the thrombin-inhibiting effect of incubated fibrinogen. Amer. J. Physiol. 197: 575 1959;
    PubMedGoogle Scholar
  • 13 Wallen P, Bergström K. Action of thrombin on plasmin digested fibrinogen. Acta chem. scand. 12: 574 1958;
    CrossrefPubMedGoogle Scholar